Barclays
CYT

Barclays’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Barclays’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed – – 5227
2022
Q2 		$0 Sell
100
-2,934
-97% -$7.49K ﹤0.01% 5356
2022
Q1 		$12K Buy
+3,034
New +$17.3K ﹤0.01% 4575

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays's CYT Position: Q3 2022 in Review

Barclays sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2022, closing a stake of 100 shares.

Barclays first reported a position in CYT in Q1 2022 and held it in 2 quarters. The position peaked at $12K in Q1 2022. 37 funds tracked by Wall St. Rank hold CYT as of Q3 2022.

  • Barclays reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Barclays sold 100 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2022.
  • Barclays first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Barclays's Cyteir Therapeutics, Inc. Common Stock position peaked at $12K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.